Ige Olusimbo K, Ayandipo Esther O
Malaria Action Program for States, Oyo Office, Ibadan, Nigeria.
Malariaworld J. 2014 Feb 4;5:2. doi: 10.5281/zenodo.10878438. eCollection 2014.
In the era of valuable and costly artemisinin-based combination therapy (ACT) for malaria it has been recommended that the use of ACTs is restricted to only those with confirmed positive malaria diagnosis. The potential benefits of rapid diagnostic tests (RDTs) on anti-malarial drug consumption have been demonstrated in a number of clinical trials. It is unknown if the introduction of RDTs in Nigeria has achieved the desired goal of reducing ACT consumption. This article assesses the impact of a state-wide roll-out of RDTs on ACT prescription in Oyo State, Nigeria.
ACT prescribing patterns for febrile patients were compared pre- and post-RDT introduction in 106 primary health care facilities. Routine data from the national malaria control programme monthly facility summary forms were extracted for three months before and after the RDT intervention and compared using a 'before and after' design.
RDT testing rates for patients with fever revealed no trend; mean testing rate in the post RDT period was 64.5%. The mean malaria positivity rate was 71.3%, which equalled a proportional morbidity rate of 45.9% of all fever cases. ACT treatment to confirmed case ratio was consistently above the expected value of one and the ratio of treatment to tested patient exceeded one (mean ratio of 1.1) for the three months post RDT. The absolute number of ACT doses prescribed increased remarkably after the introduction of RDTs and ACTs revealing an extra utilisation of 14,199 doses, 5,534 (±517) versus 10,267 (±2,452), p<0.001. Relative Risk of ACT prescription in the post RDT period was 1.71 (1.33-2.25).
There is notable non-adherence to RDT results, with an increase in ACT prescriptions after the initial introductory period for RDTs. This over reliance on ACTs for the management of non-malaria illness could compromise gains from reducing malaria morbidity and mortality and needs to be addressed urgently.
在使用基于青蒿素的联合疗法(ACT)治疗疟疾成本高昂且药物珍贵的时代,有人建议ACT仅用于确诊为疟疾阳性的患者。多项临床试验已证明快速诊断检测(RDT)在减少抗疟药物消耗方面的潜在益处。目前尚不清楚在尼日利亚引入RDT是否实现了减少ACT消耗的预期目标。本文评估了在尼日利亚奥约州全州范围内推广RDT对ACT处方的影响。
比较了106家初级卫生保健机构在引入RDT前后发热患者的ACT处方模式。从国家疟疾控制项目每月的机构总结表中提取RDT干预前后三个月的常规数据,并采用“前后”设计进行比较。
发热患者的RDT检测率无明显趋势;RDT引入后的平均检测率为64.5%。疟疾平均阳性率为71.3%,相当于所有发热病例中45.9%的发病率。确诊病例的ACT治疗比例始终高于预期值1,在RDT引入后的三个月中,治疗与检测患者的比例超过1(平均比例为1.1)。引入RDT和ACT后,ACT处方的绝对剂量显著增加,额外使用了14199剂,从5534(±517)剂增加到10267(±2452)剂,p<0.001。RDT引入后ACT处方的相对风险为1.71(1.33 - 2.25)。
对RDT结果存在明显的不依从现象,在RDT引入初期后ACT处方增加。这种对ACT用于非疟疾疾病管理的过度依赖可能会损害降低疟疾发病率和死亡率所取得的成果,需要紧急加以解决。